Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00056
|
|||||
| Drug Name |
Lamotrigine
|
|||||
| Synonyms |
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine; BW 430C; BW-430C; Crisomet; Desitin Brand of Lamotrigine; EUR-1048; Faes Brand of Lamotrigine; GI 267119X; GW 273293; Glaxo Wellcome Brand of Lamotrigine; GlaxoSmithKline Brand of Lamotrigine; Juste Brand of Lamotrigine; L 3791; Labileno; Lamictal; Lamictal (TN); Lamictal Cd; Lamictal ODT; Lamictal XR; Lamictin; Lamictin (TN); Lamiktal; Lamitor; Lamotrigina; Lamotrigina [Spanish]; Lamotrigine (JAN/USAN/INN); Lamotrigine [USAN:INN:BAN]; Lamotriginum; Lamotriginum [Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bipolar disorder [ICD11: 6A60-6A61] | Approved | [1] | |||
| Epilepsy [ICD11: 8A6Z] | Approved | [1] | ||||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H7Cl2N5
|
|||||
| Canonical SMILES |
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
|
|||||
| InChI |
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
|
|||||
| InChIKey |
PYZRQGJRPPTADH-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 84057-84-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 256.089 | Topological Polar Surface Area | 90.7 | ||
| Heavy Atom Count | 16 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103199382
, 103940000
, 104179107
, 104304778
, 11111377
, 11113342
, 111978157
, 11528749
, 117872151
, 12013463
, 121361621
, 124658861
, 124799528
, 124880544
, 124880545
, 124880546
, 14823602
, 17405249
, 24278792
, 26719658
, 29222992
, 46386680
, 46505408
, 47810853
, 48259345
, 48416154
, 50100261
, 50104089
, 50104090
, 53777794
, 53787568
, 56423136
, 5669156
, 57322032
, 58107296
, 76843584
, 7847420
, 7979720
, 81092819
, 8152444
, 85231112
, 855818
, 90341162
, 91148150
, 92304062
, 92308151
, 92308280
, 92308924
, 92709766
, 93166952
|
|||||
| ChEBI ID |
ChEBI:6367
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Lamotrigine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol. 2012 Mar 15;83(6):805-14. | |||||
| 3 | Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008 Dec;55(8):1364-75. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.